Avita Medical is growing revenue but still burns cash, scores below the quality floor, and trades above its analyst target, leaving little room for upside while earnings execution stays inconsistent.
Thesis pillars
- Cash Burn Below Quality Floor→Stable
- Price Above Analyst Target→Stable
- Revenue Reacceleration Recent Quarters↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 18, 2026, based on the 10-K filed Feb 12, 2026
Avita Medical, Inc. (RCEL) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $16.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality.
AVITA Medical sells acute wound care products led by RECELL, an FDA-approved device that makes a Spray-On Skin cell suspension from a small donor skin sample at the point of care for burns and full-thickness skin defects, plus the PermeaDerm and Cohealyx wound matrices. Sales... Read more
Sell if holding. Engine safety override at $16.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: aggressive.
About Avita Medical, Inc.
About Avita Medical, Inc.
AVITA Medical, a Valencia, California wound care company, reported a net loss of $48.6 million for 2025 against $61.8 million in 2024, bringing its cumulative deficit to $408.4 million. Its RECELL system, FDA-approved since September 2018 for thermal burns and later for full-thickness skin defects, sells mainly in the United States, where about 140 specialized burn centers treat most severe burn patients.
RECELL lets a clinician turn a thin donor skin sample into a suspension of the patient's own skin cells in about 30 minutes, sparing donor skin compared with conventional grafting. The portfolio spans RECELL 1920, RECELL GO and RECELL GO mini, which received FDA approval on December 23, 2024 for wounds up to 480 square centimeters. Complementary products include PermeaDerm, a biosynthetic wound matrix made by the company and distributed exclusively in the U.S. under agreements with Stedical, and Cohealyx, a collagen dermal matrix developed with Regenity that launched in the U.S. on April 1, 2025. Hospitals are paid through MS-DRG inpatient payments and physicians through Category I CPT codes 15011 to 15018 effective January 1, 2025, and a Medicare New Technology Add-On Payment began October 1, 2025 for certain non-thermal full-thickness defects. Outside the U.S., sales run through third-party distributors following CE mark approval of RECELL GO in September 2025. The company employed about 226 people and paused further commercial investment in vitiligo.
Show full overview
Regulatory and financing concentration frames the risk. The 10-K states the business is highly dependent on the September 2018 FDA premarket approval, and a modification, suspension or revocation of it would have a material adverse effect. On January 13, 2026 the company entered a five-year senior secured Perceptive credit facility of up to $60 million, funded $50 million at closing and repaid the $40.0 million OrbiMed debt; a net revenue shortfall against agreed levels would put it in default. Some material components are single-sourced, so a supplier disruption might delay production at the Ventura plant and add to losses that may require dilutive equity financing.
See also: Healthcare · Medical Devices
From Avita Medical, Inc.'s most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated 2026-10-29Recent Developments — Avita Medical, Inc.
Latest news
- NEWS AVITA Medical Schedules Third Quarter 2026 Financial Results Announcement — fiscal.ai Oct 21, 2026 neutral
- NEWS BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15 — benzinga Oct 12, 2026 positive
- NEWS AVITA Medical Q2 2026 Earnings Call Transcript — benzinga Oct 12, 2026 neutral
Generated 2026-10-29T11:08:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHregulatoryFDA PMA approval for RECELL10-K Item 1A: 'Our business is highly dependent on the PMA we received in September 2018 from the FDA'
- HIGHSuppliersingle-sourced material components10-K Item 1A: 'in 2023, we single-sourced some of our material components'
- MEDIUMGeographicUnited States primary market10-K Item 1A: 'in the United States, our current primary market'
- MEDIUMCustomerspecialized burn centers10-K Item 1: 'approximately 140 specialized burn centers treating the majority of severe burn patients'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -57.0%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.35. Score 4.8/10, moderate confidence.
Analyst target $11.56 reached (−30.0% from $16.50); no take-profit level is published. Prior stop was $15.35. Stop-loss: $15.35.
Concentration risk — Regulatory: FDA PMA approval for RECELL; Concentration risk — Supplier: single-sourced material components; Target reached (-30.0% upside).
Avita Medical, Inc. trades at a P/E of N/A (forward -38.9). TrendMatrix value score: 4.1/10. Verdict: Sell.
10 analysts cover RCEL with a consensus score of 3.9/5. Average price target: $14.
What does Avita Medical, Inc. do?AVITA Medical sells acute wound care products led by RECELL, an FDA-approved device that makes a Spray-On Skin cell...
AVITA Medical sells acute wound care products led by RECELL, an FDA-approved device that makes a Spray-On Skin cell suspension from a small donor skin sample at the point of care for burns and full-thickness skin defects, plus the PermeaDerm and Cohealyx wound matrices. Sales are mainly in the U.S., concentrated in about 140 specialized burn centers, with distributors abroad. The company is loss-making, with a net loss of $48.6 million in 2025.